<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03638726</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 00001211</org_study_id>
    <nct_id>NCT03638726</nct_id>
  </id_info>
  <brief_title>Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification</brief_title>
  <official_title>Combined Subconjunctival Atropine and Intracameral Epinephrine Injection for Pupil Dilation in Phacoemulsification Under Peribulbar Anesthesia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dar El Oyoun Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dar El Oyoun Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mydriatic eye drops are routinely used before phacoemulsification but they are not free of
      drawbacks. Several alternatives were tried to overcome their limitations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include 20 patients with bilateral cataract (40 eyes). The experimental group
      will include eyes for which a new injectable mydriatic combination are used to dilate the
      pupil. The control group will include cases where standard mydriatic eye drops are used.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2018</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized clinical study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Preoperative and postoperative assessment will be done by a masked observer.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Intraoperative pupil diameter</measure>
    <time_frame>1 day</time_frame>
    <description>Intraoperative pupil diameter measurements of involved eye in mm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>Starting from first postoperative day till one month.</time_frame>
    <description>Complications such as subconjunctival hemorrhage or corneal edema
[Time Frame: starting from the first postoperative day till one month]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative corneal thickness</measure>
    <time_frame>1 month after surgery</time_frame>
    <description>Measured by specular microscopy in ( mm )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative corneal endothelial density</measure>
    <time_frame>1 month after surgery</time_frame>
    <description>Measured by specular microscopy in ( cell number/mm2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pupil diameter</measure>
    <time_frame>one day, one week and one month after surgery</time_frame>
    <description>Postoperative diameter of involved eye in mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative visual acuity</measure>
    <time_frame>One day, one week and one month after surgery</time_frame>
    <description>Postoperative best corrected distance visual acuity in logmar units.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative intraocular pressure (IOP)</measure>
    <time_frame>One day, one week and one month after surgery</time_frame>
    <description>Postoperative IOP measured in mmHg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cataract</condition>
  <condition>Mydriasis</condition>
  <condition>Adverse Drug Event</condition>
  <arm_group>
    <arm_group_label>Atropine sulfate and Epinephrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Perioperative pupil dilation is achieved by combined use of subconjunctival Atropine sulfate 0.6 mg ( parasympathetic antagonist) and intracameral Epinephrine 1:100000 ( sympathetic agonist).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical cyclopentolate and phenylephrine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Preoperative pupil dilation was achieved using topical cyclopentolate and phenylephrine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atropine sulfate and epinephrine</intervention_name>
    <description>Experimental arm:Combined use of subconjunctival atropine sulfate 0.6 mg ( parasympathetic antagonist) and intracameral epinephrine 1:100000 ( sympathetic agonist). Control arm :topical mydriatics are used for pupil dilation.</description>
    <arm_group_label>Atropine sulfate and Epinephrine</arm_group_label>
    <other_name>Atropine (Misr.co), Epinephrine (Misr.co)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical cyclopentolate and phenylephrine</intervention_name>
    <description>Control arm: Preoperative cyclopentolate and phenylephrine eye drops are used.</description>
    <arm_group_label>Topical cyclopentolate and phenylephrine</arm_group_label>
    <other_name>Cyclophrine eye drops</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cases of bilateral visually significant cataract

        Exclusion Criteria:

          -  Poor pupil dilation(less than 6 mm diameter).

          -  History of previous eye surgery or trauma

          -  History of use of eye drops affecting pupil size such as pilocarpine.

          -  Known drug allergy to cyclopentolate,phenylephrine, atropine sulfate or epinephrine.

          -  Pediatric age group (less than 18 years old).

          -  Pupil abnormalities, such as anisocoria or neurological disorders.

          -  Associated glaucoma, uveitis, corneal, retinal or optic nerve disease.

          -  Cases scheduled for phacoemulsification under general anaesthesia (to exclude possible
             ocular and systemic effects or interactions of anaesthetic agents).

          -  Patients with bleeding tendency or on anti-coagulant therapy (because peribulbar and
             subconjunctival injections are used).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nossair</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dar El Oyoun Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ewais</last_name>
    <phone>+01223638543</phone>
    <email>waelewais74@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ali</last_name>
    <phone>+01005005707</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dar El Oyoun Hospital</name>
      <address>
        <city>Cairo</city>
        <state>Giza</state>
        <zip>1261</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khaled Samir, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>February 5, 2018</study_first_submitted>
  <study_first_submitted_qc>August 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2018</study_first_posted>
  <last_update_submitted>October 7, 2018</last_update_submitted>
  <last_update_submitted_qc>October 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dar El Oyoun Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Ashraf Nossair, MD</investigator_full_name>
    <investigator_title>Associate Professor of Ophthalmology, Cairo University</investigator_title>
  </responsible_party>
  <keyword>intraoperative mydriasis</keyword>
  <keyword>subconjunctival atropine</keyword>
  <keyword>intracameral epinephrine</keyword>
  <keyword>cataract surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Mydriasis</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atropine</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Cyclopentolate</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Identity and names of participant will be hidden. Data related to outcome measures can be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

